Inclusion Criteria

Lists of Inclusion and Exclusion criteria:

- Patients must have histologically confirmed hepatocellular carcinoma

- Patients must have measurable disease by CT scan

- Have not received previous palliative systemic chemotherapy for metastatic disease.
(Adjuvant chemotherapy or radiation therapy for non target lesion can be allowed.)

- Patients progress after previous local treatment and at the time of randomization is
at least 4 weeks after the last interventional therapy (Hepatic Artery Infusion,
Trans-Artery Embolization or Trans-Artery Chemo-Embolization) or at least 4 weeks
after the last radiotherapy/ablation/ Percutaneous Ethanol Injection to the target
lesion.

- WHO 0-2 grades (Karnofsky Performance Score ≥ 70)

- Patients must have adequate organ and marrow function:

- Neutrophilus ≥ 1.5 x 10^9/L

- Platelets ≥ 75 x 10^9/L

- Asparagine AminoTransferase, Alanine AminoTransferase < 2.5 x Upper Normal
Limit(UNL)

- Total Bilirubin ≤ 1.5 x UNL

- International Normalized Ratio < 1.5

- Child stage A or B

- Creatinine ≤ 1.5 X UNL

Exclusion Criteria:

- Documented allergy to platinum compound or to other study drugs.

- Active Gastro-Intestinal bleeding and active haematologic malignancy

- Previous liver transplantation.

- Patients concomitantly receiving any other anti-cancer therapy.

- Patients who are receiving any other study treatments.

- Pregnant or lactating women or women of childbearing potential without proper
contraceptive methods.

- History of other malignant diseases, except cured basal cell carcinoma of skin and
cured carcinoma in-situ of uterine cervix.

- Central nervous system metastasis

- Other serious illness or medical conditions

- Neuropathy ≥ grade 2

The above information is not intended to contain all considerations relevant to a
patient's potential participation in a clinical trial.